Oxford BioDynamics is developing effective applications in a number of fields where prevalence is high, diagnosis poor and where current therapies do not provide adequate improvement to patient’s health and quality of life.
The diagnostic output of OBD EpiSwitch™ enables the development of innovative therapies that target diseases such as, for breast cancer, prostate cancer, malignant melanoma, liver cancer, Alzheimer’s, Parkinson’s and Osteoporosis. OBD aims to provide patients with the best personalised treatment and care choices, for the early diagnosis, monitoring and prognosis of these diseases.
